We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-8.7%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
-$209M
(-4.4%)
Cap. Flow
+$390M
Cap. Flow
% of AUM
8.66%
Top 10 Holdings %
Top 10 Hldgs %
40.95%
Holding
117
New
19
Increased
33
Reduced
18
Closed
25
Top Buys
| 1 |
Merck
MRK
|
+$187M |
| 2 |
Intuitive Surgical
ISRG
|
+$94.9M |
| 3 |
Humana
HUM
|
+$83.2M |
| 4 |
Biogen
BIIB
|
+$79.4M |
| 5 |
UnitedHealth
UNH
|
+$65.8M |
Top Sells
| 1 |
Pfizer
PFE
|
+$123M |
| 2 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$113M |
| 3 |
Eli Lilly
LLY
|
+$95.2M |
| 4 |
HOLX
Hologic
HOLX
|
+$81.5M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$79.1M |
Sector Composition
| 1 | Healthcare | 97.22% |
| 2 | Financials | 0.53% |
| 3 | Technology | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.15B
| $297M | 6.58% |
+3,300,000
| New | +$470M |
|
2
AstraZeneca
AZN
$261B
| $245M | 5.45% |
1,850,000
+416,400
| +29% | +$49.9M |
|
3
AbbVie
ABBV
$431B
| $238M | 5.27% |
1,466,100
-518,900
| -26% | -$75.4M |
|
4
Arvinas
ARVN
$534M
| $196M | 4.35% |
2,915,300
+387,327
| +15% | +$26.4M |
|
5
Elevance Health
ELV
$84.8B
| $196M | 4.35% |
399,400
+78,400
| +24% | +$35.8M |
|
|
6
Merck
MRK
$305B
| $194M | 4.32% |
+2,370,000
| New | +$187M |
|
7
Avantor
AVTR
$7.65B
| $192M | 4.25% |
5,668,300
+876,300
| +18% | +$31.3M |
|
8
Baxter International
BAX
$11.4B
| $149M | 3.3% |
1,915,500
+150,500
| +9% | +$12.6M |
|
9
Zentalis Pharmaceuticals
ZNTL
$340M
| $147M | 3.25% |
3,176,999
+461,999
| +17% | +$24.9M |
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $146M | 3.24% |
1,231,000
+91,000
| +8% | +$11.3M |
|
11
Vertex Pharmaceuticals
VRTX
$121B
| $142M | 3.16% |
545,600
+265,600
| +95% | +$63M |
|
|
12
UnitedHealth
UNH
$380B
| $132M | 2.94% |
259,600
+136,500
| +111% | +$65.8M |
|
13
United Therapeutics
UTHR
$22.6B
| $129M | 2.86% |
718,946
+183,946
| +34% | +$35M |
|
|
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $119M | 2.64% |
1,131,400
+119,400
| +12% | +$11.6M |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $115M | 2.54% |
1,393,000
+586,600
| +73% | +$60M |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $109M | 2.42% |
6,475,400
-479,600
| -7% | -$7.09M |
|
17
Neurocrine Biosciences
NBIX
$17.3B
| $109M | 2.41% |
1,160,000
-100,000
| -8% | -$8.47M |
|
18
Iovance Biotherapeutics
IOVA
$2.12B
| $101M | 2.23% |
6,043,219
+2,263,219
| +60% | +$35M |
|
|
19
Intuitive Surgical
ISRG
$138B
| $98M | 2.18% |
+325,000
| New | +$94.9M |
|
|
CTLT
20
DELISTED
CATALENT, INC.
CTLT
| $86.7M | 1.92% |
782,000
+87,000
| +13% | +$9.08M |
|
|
21
Humana
HUM
$49B
| $86.6M | 1.92% |
+198,900
| New | +$83.2M |
|
22
Syndax Pharmaceuticals
SNDX
$2.08B
| $83.8M | 1.86% |
4,823,400
| – | – |
|
|
23
Biogen
BIIB
$29.1B
| $76.9M | 1.71% |
+365,000
| New | +$79.4M |
|
24
Ultragenyx Pharmaceutical
RARE
$3.12B
| $63.1M | 1.4% |
869,000
+169,000
| +24% | +$11.8M |
|
25
Johnson & Johnson
JNJ
$595B
| $62.7M | 1.39% |
+354,000
| New | +$60.2M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH